Page 10 - Celularity Inc News Today

FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing...

/PRNewswire/ -- The last decade has witnessed a shift in lifestyle especially among the working population who are spending increased number of hours at office...

Increasing demand for blood transducers propelling overall market; COVID-19 pandemic outbreak boosts market growthRising prevalence of chronic diseases such as diabetes expected to augment market

Researchers found that second-line immunosuppression for severe immune-related adverse events was associated with impaired survival outcomes among patients with advanced melanoma.

Miami, FL (PRWEB) October 17, 2022 -- The Global Wellness Institute (GWI), the leading research and educational resource for the $4.4 trillion global wellness

/PRNewswire/ -- The stem cell umbilical cord blood (UCB) market has been segmented by end-user (pharmaceutical, research institutes, hospitals, and biobanks)...

Global Stem Cell Umbilical Cord Blood (UCB) Market 2022-2026 The analyst has been monitoring the stem cell umbilical cord blood (UCB) market and it is...

Celularity named Dr. Adrian Kilcoyne as EVP, chief medical officer and head of global medical affairs, patient safety and patient affairs.  

Veteran pharmaceutical executive brings more than 15 years of proven oncology and immunology experience...

/PRNewswire/ -- Immunis Inc., a private biotechnology company developing an immunomodulatory secretome for age and disease-related immune decline in Phase 1/2a...